RT Journal Article
SR Electronic
T1 Digital gait outcomes for ARSACS: discriminative, convergent and ecological validity in a multi-center study (PROSPAX)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.04.24300722
DO 10.1101/2024.01.04.24300722
A1 Beichert, Lukas
A1 Ilg, Winfried
A1 Kessler, Christoph
A1 Traschütz, Andreas
A1 Reich, Selina
A1 Santorelli, Filippo M.
A1 Başak, Ayşe Nazli
A1 Gagnon, Cynthia
A1 ,
A1 Schüle, Rebecca
A1 Synofzik, Matthis
YR 2024
UL http://medrxiv.org/content/early/2024/01/04/2024.01.04.24300722.abstract
AB Background With treatment trials on the horizon, this study aimed to identify candidate digital-motor gait outcomes for Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS), capturable by wearable sensors with multi-center validity, and ideally also ecological validity during free walking outside laboratory settings.Methods Cross-sectional multi-center study (4 centers), with gait assessments in 36 subjects (18 ARSACS patients; 18 controls) using three body-worn sensors (Opal, APDM) in laboratory settings and free walking in public space. Sensor gait measures were analyzed for discriminative validity from controls, and for convergent (i.e. clinical and patient-relevance) validity by correlations with SPRSmobility (primary outcome) and SARA, SPRS and FARS-ADL (exploratory outcomes).Results Of 30 hypothesis-based digital gait measures, 14 measures discriminated ARSACS patients from controls with large effect sizes (|Cliff’s δ| > 0.8) in laboratory settings, with strongest discrimination by measures of spatiotemporal variability Lateral Step Deviation (δ=0.98), SPcmp (δ=0.94) and Swing CV (δ=0.93). Large correlations with the SPRSmobility were observed for Swing CV (Spearman’s ρ = 0.84), Speed (ρ=-0.63) and Harmonic Ratio V (ρ=-0.62). During supervised free walking in public space, 11/30 gait measures discriminated ARSACS from controls with large effect sizes. Large correlations with SPRSmobility were here observed for Swing CV (ρ=0.78) and Speed (ρ=-0.69), without reductions in effect sizes compared to lab settings.Conclusion We identified a promising set of digital-motor candidate gait outcomes for ARSACS, applicable in multi-center settings, correlating with patient-relevant health aspects, and with high validity also outside lab settings, thus simulating real-life walking with higher ecological validity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the DFG under the frame of EJP-RD network PROSPAX (No 441409627; to M.S., R.S, F.S., C.G., A.N.B) and by the Clinician Scientist program "PRECISE.net" funded by the Else Kroener-Fresenius-Stiftung (to L.B., A.T., and M.S.). A.T. received funding from University of Tuebingen, medical faculty, for the Clinician Scientist Program Grant #439-0-0. F.M.S. is supported in part by the Italian Ministry of Health (the EJP-RD network PROSPAX; Ricerca Finalizzata RF-2019-12370417; Ricerca Corrente 2023, RC 5x1000).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of the University of Tuebingen gave ethical approval for this work (AZ 824/2019BO2)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData will be made available upon reasonable request and as patient consent allows.